Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Next Previous
Trial Profile

A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Ankylosing spondylitis; Axial spondyloarthritis; Crohn's disease; Inflammation; Juvenile rheumatoid arthritis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Acronyms CHERISH
  • Sponsors UCB Biopharma

Most Recent Events

  • 15 Jun 2024 Results investigating the longitudinal PK and safety of the use of CZP during pregnancy and post-partum by measuring plasma CZP concentration and monitoring treatment emergent adverse events , presented at the 25th Annual Congress of the European League Against Rheumatism
  • 13 Jun 2024 According to UCB media release, data of CHERISH trial having data build on previous pharmacokinetic studies CRIB and CRADLE , will be presented at the European Congress of Rheumatology, EULAR 2024, and provide evidence to inform personalized treatment decisions for patient populations with high unmet need
  • 30 May 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top